Bioequivalency Study of 300 mg Lithium Carbonate Under Fasting Conditions
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane lithium carbonate 300 mg
extended release tablet formulation compared to Solvay's Lithobid 300 mg extended release
tablet under fasting conditions using a single-dose, randomized, 2 treatment, 2-period,
2-sequence crossover design.